Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, Shanghai Jiao Tong University
1 Sept 2016 → 30 Jun 2022
Award Date: 30 Jun 2022
Master, Shanghai Jiao Tong University
1 Sept 2013 → 30 Jun 2016
Award Date: 30 Jun 2016
External positions
Postdoctoral, Zhejiang University
5 Sept 2022 → 27 Nov 2024
Keywords
- QR180 Immunology
- Immunotherapy
- Myeloid-derived suppressor cells (MDSC)
Person Types
- Staff
Fingerprint
Dive into the research topics where Anjie Zheng is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Active
-
CPSF: Exploring the tumor immune microenvironment in glioma-bearing mice through the "Window of Opportunity" and applying immunotherapy to glioma
1/01/25 → 31/12/26
Project: Governmental Research Project
-
NSFC: Development and evaluation of biomaker in tumor immunotherapy under treatment with all-trans retinoic acid liposome
1/01/24 → 31/12/25
Project: Governmental Research Project
Research output
- 6 Article
-
Characterization of mRNA-LNP structural features and mechanisms for enhanced mRNA vaccine immunogenicity
Wu, K., Xu, F., Dai, Y., Jin, S., Zheng, A., Zhang, N. & Xu, Y., Dec 2024, In: Journal of Controlled Release. 376, p. 1288-1299 12 p.Research output: Contribution to journal › Article › peer-review
-
Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models
Shi, S., Zhang, L., Zheng, A., Xie, F., Kesse, S., Yang, Y., Peng, J. & Xu, Y., Dec 2024, In: Cancer Immunology, Immunotherapy. 73, 12, 248.Research output: Contribution to journal › Article › peer-review
Open Access -
MDSC-targeted liposomal all-trans retinoic acid suppresses mMdscs and improves immunotherapy in HBV infection
Kesse, S., Xu, Y., Shi, S., Jin, S., Ullah, S., Dai, Y., He, M., Zheng, A., Xu, F., Du, Z., Alolga, R. N. & Peng, J., 2024, In: Expert Opinion on Drug Delivery. 21, 2, p. 347-363 17 p.Research output: Contribution to journal › Article › peer-review
-
Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy
Xie, F., Zhang, L., Shi, S., Zheng, A., Di, J., Jin, S., Miao, X., Wu, F., Chen, X., Zhang, Y., Wei, X. & Xu, Y., 2022, In: mAbs. 14, 1, 2115205.Research output: Contribution to journal › Article › peer-review
Open Access4 Citations (Scopus) -
Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment
Zheng, A., Xie, F., Shi, S., Liu, S., Long, J. & Xu, Y., 12 Apr 2022, In: Frontiers in Immunology. 13, 829391.Research output: Contribution to journal › Article › peer-review
Open Access10 Citations (Scopus)